Table of Contents Author Guidelines Submit a Manuscript
Canadian Respiratory Journal
Volume 2017, Article ID 3685261, 7 pages
https://doi.org/10.1155/2017/3685261
Research Article

Galactomannan in Bronchoalveolar Lavage Fluid for Diagnosis of Invasive Pulmonary Aspergillosis with Nonneutropenic Patients

1Department of Pulmonology, The Affiliated Hospital of Ningbo University, 247 Renmin Road, Ningbo, Zhejiang 315020, China
2Department of Microbiology, The Affiliated Hospital of Ningbo University, 247 Renmin Road, Ningbo, Zhejiang 315020, China

Correspondence should be addressed to Zaichun Deng; moc.anis@bzcnoel and Zhongbo Chen; moc.oohay@bzcnoel

Received 8 July 2017; Revised 4 September 2017; Accepted 12 September 2017; Published 13 November 2017

Academic Editor: Alice M. Turner

Copyright © 2017 Qidong Zhuang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. We evaluated the utility of galactomannan (GM) in bronchoalveolar lavage fluid (BALF) for the diagnosis of invasive pulmonary aspergillosis (IPA) in nonneutropenic patients. Methods. A total of 183 patients were included in the final analysis. Bronchoscopies and the detection of GM in BALF were all performed on them. Results. Ten cases of IPA were diagnosed. ROC data demonstrated that, for diagnosing IPA, an optimal cutoff value for GM in BALF of 0.76 yielded a sensitivity of 100.0% and a specificity of 76.2%. Symptoms and radiological findings had no significant difference between proven or probable IPA group and non-IPA group. In our case-control analysis, although nine patients with false-positive results received treatment with Piperacillin/tazobactam, there was no significant difference between case and control group. Conclusions. BALF GM detection is a valuable adjunctive diagnostic tool. Our retrospective study suggests that the optimal value of GM detection in BALF is 0.76 in nonneutropenic patients.